Article

Novartis presents latest data on verteporfin for AMD

Researchers working with Novartis Ophthalmics presented data Monday onwet age-related macular degeneration (AMD) and verteporfin (Visudyne) therapyduring a session on AMD.Entitled "Age-Related Macular Degeneration: Photodynamic Therapy,"the session highlighted three papers that focused on verteporfin.

Related Videos
Ophthalmology Times: Kathryn Colby, MD, PhD, reflects on National Women Physicians Day
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
Related Content
Image credit: Mercy Ships
February 4th 2025

Mercy Ships delivers a lifeline for eye health in Africa’s remote communities

2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
December 13th 2024

California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco

Study investigates neurological impact of diabetic vitreous hemorrhage
February 4th 2025

Study investigates neurological impact of diabetic vitreous hemorrhage

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Prevent Blindness names February as AMD and Low Vision Awareness Month
February 4th 2025

Prevent Blindness names February as AMD and Low Vision Awareness Month

CHMP of the European Medicines Agency issues positive opinion on 2 aflibercept biosimilars
February 3rd 2025

CHMP of the European Medicines Agency issues positive opinion on 2 aflibercept biosimilars

© 2025 MJH Life Sciences

All rights reserved.